Abstract
The scientific and regulatory issues that are associated with the possible introduction of 'follow-on' versions of protein drug products are the topic of considerable debate at present. Because of the differences between protein drug products and small-molecule drugs, the development of follow-on versions of protein products presents more complex scientific challenges than those presented by the development of generic versions of small-molecule drugs. Here, with a view to illustrating the Food and Drug Administration's (FDA's) scientific reasoning and experience in this area, we discuss past examples of the FDA's actions involving the evaluation of various types of follow-on and second-generation protein products and within-product manufacturing changes. The FDA believes its evaluation of the safety and effectiveness of follow-on protein products will evolve as scientific and technological advances in product characterization and manufacturing continue to reduce some of the complexity and uncertainty that are inherent in the manufacturing of protein products.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
United States Code (USC) § 505(b)(2). FDA web site [online], (1999).
Office of Science and Technology Policy. Coordinated Framework for Regulation of Biotechnology. United States Regulatory Agencies Unified Biotechnology web site [online], (26 June 1986).
FDA regulations, 21 CFR Part 640, Subpart H. FDA web site [online], (2006).
Antman, E. M., Wenger, T. L., Butler, V. P., Haber, E. & Smith, T. W. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific fab antibody fragments. Circulation 81, 1744–1752 (1990).
FDA web site [online], (2006).
Boven, K. et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dial. Transplant. 20 (Suppl. 3), iii33–iii40 (2005).
Schellekens, H. & Jiskoot, W. Eprex-associated pure red cell aplasia and leachates. Nature Biotech. 24, 613–614 (2006).
Sharma, S. Ryan, M. H. & Boven, K. Reactions to Eprex's adverse reactions. Nature Biotech. 24, 1199–1200 (2006).
Product Approval Information — Licensing Action, PLA: #95–0979/ELA: # 95–0975. FDA web site [online], (1996).
“Follow-on protein products”. Statement of Janet Woodcock, M.D., Deputy Commissioner, Chief Medical Officer, Food and Drug Administration before the Committee on oversight and government reform United States House of Representatives, 26 March 2007. FDA web site [online], (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Woodcock, J., Griffin, J., Behrman, R. et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 6, 437–442 (2007). https://doi.org/10.1038/nrd2307
Issue Date:
DOI: https://doi.org/10.1038/nrd2307
This article is cited by
-
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One
BioDrugs (2022)
-
An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology
Nature Reviews Rheumatology (2017)
-
Active Surveillance of Follow-on Biologics: A Prescription for Uptake
Drug Safety (2017)
-
Assessing the Immunogenicity of Biopharmaceuticals
BioDrugs (2016)
-
Evaluation of Ion Mobility-Mass Spectrometry for Comparative Analysis of Monoclonal Antibodies
Journal of the American Society for Mass Spectrometry (2016)
